Cancer Care

Cleveland BioLabs has enrolled all the patients in its Phase II clinical trial of Curaxin CBLC102 in advanced, hormone-refractory prostate cancer.

Thirty-two patients from four medical centers in the U.S. will be evaluated prior to treatment with the drug, as well as at one-month intervals for a maximum of six months.

The trial’s goals are to confirm safety and tolerability of the drug in patients with hormone-refractory metastatic prostate cancer and to evaluate the efficacy of the drug by assessing prostate-specific antigen levels, reductions in tumor size and disease-free survival periods.

The company said it expects results to be available in the fourth quarter of this year.

Source : fdanews.co

The number of new diagnoses of prostate cancer across Bradford has jumped by nearly 80 per cent in eight years, figures have revealed.

Latest figures show 212 new cases were diagnosed in the area in 2005 compared with 118 in 1997. Numbers of diagnoses peaked at 221 in 2004.

Prostate cancer is the most common male cancer in the UK, accounting for almost a quarter of male cancers. In 2005, the year for which the latest figures are available, 28,886 new diagnoses were made in England compared with 19,878 in 1997. About 10,000 men die from the disease each year.
(more…)

A LOTHIANS support group has urged men to check themselves out for prostate cancer as part of an awareness week.
Health chiefs from NHS Lothian are already urging people to do more to protect themselves from the disease.

The Scottish Prostate Cancer Support Groups, which meet in Edinburgh and Livingston, have warned men need to be vigilant against it.
(more…)

Australian researchers have found an unlikely link between prostate cancer and osteoporosis.

Scientists at the Garvan Institute found men with prostate cancer face a 50 per cent higher risk of a fracture.

Researchers studied more than 800 men from the New South Wales city of Dubbo for 20 years.

They say the reasons why prostate cancer might cause osteoporosis remain a mystery.

But they say anyone with prostate cancer should think about having their bone density tested.

This month, the Deseret News/Intermountain Hotline introduces an online component. Besides calling in to ask questions about prostate cancer of Dr. Jay Bishoff and Dr. Scott Chidester, urologists at the Intermountain Urological Institute at Intermountain Medical Center in Murray, readers also submitted questions by e-mail. Here, Chidester tackles the most common questions asked.

Most of the e-mails centered around two complications related to prostate cancer treatment, erectile dysfunction and urinary incontinence. Some of the questions are presented here, edited to remove personal, potentially identifiable information. (more…)

Los Angeles, May 26 (Xinhua) Contrary to popular opinion, lycopene, an antioxidant found in tomatoes, does not help prevent prostate cancer, a new study has found.

The new findings by researchers at the US Fred Hutchinson Cancer Research Center (FHCRC) contradict a long-held theory that touts lycopene as a magic bullet for prostate cancer, according to the May issue of the journal Cancer Epidemiology, Biomarkers and Prevention.
(more…)

Recent studies have indicated that the protein known as TRPM8 plays an important role in prostate cancer: high levels of TRPM8 have been found in prostate carcinoma compared to normal prostate epithelial cells, and TRPM8 has been suggested as a specific marker and therapeutic target in prostate cancer. However, the regulation of and changes in TRPM8 during prostate cancer progression have remained unclear.
(more…)

NEW BRUNSWICK, N.J., May 24 /PRNewswire/ — On Friday, June 15, New Jersey residents can wear sneakers to work AND raise funds for prostate cancer research and awareness. “Sneakers@Work Day,” a prostate cancer awareness day launched by Governor Jon Corzine, is being spearheaded by Betty Gallo, of Lake Hopatcong, N.J.
(more…)

Prostate cancer is the commonest male cancer in Britain, with nearly 32,000 cases diagnosed each year. One man dies every hour from the disease.
Yet most men are ignorant of the signs and symptoms, according to a survey of more than 2,500 men carried out by the Everyman Campaign.
The campaign is calling for more funding for prostate cancer research and urges men to be aware of the signs and symptoms of the disease.
(more…)

Performing less invasive laparoscopic surgery using robotic technology may improve survival rates for prostate cancer patients, according to a study by urologic oncologists at Thomas Jefferson University Hospital’s multidisciplinary Genitourinary (GU) cancer center.
(more…)